MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (124.28% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Needham & Company LLCReiterated RatingBuy$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016William BlairInitiated CoverageOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Jefferies GroupInitiated CoverageBuy$20.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.29)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.60)($0.42)($0.51)
Q2 20162($0.74)($0.45)($0.60)
Q3 20162($0.85)($0.63)($0.74)
Q4 20162($0.86)($0.60)($0.73)
(Data provided by Zacks Investment Research)
Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
DateHeadline
06/23/16 04:48 PMCollegium Pharmaceutical : Announces Positive Topline Results for Hydrocodone DETERx Clinical Study
06/22/16 03:28 PMCollegium introduces Xtampza ER capsules in US
06/22/16 07:19 AMCollegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study - [at noodls] - CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx as a second product ...
06/21/16 08:05 AMKeryx Biopharmaceuticals Appoints Two New Board Members
06/20/16 03:19 PMAllergy Treatment Market 2016-2026 Shares, Trend and Growth Report
06/20/16 09:40 AMCollegium Pharma (COLL) Says Xtampza ER Now Commercially Available - StreetInsider.com
06/20/16 09:40 AMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 08:19 AMCollegium Announces Commercial Launch of Xtampza® ER - [at noodls] - CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of XtampzaER (oxycodone) extended-release (ER) capsules in the United ...
06/14/16 07:39 AMCOLLEGIUM PHARMACEUTICAL, INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/13/16 04:02 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 09:27 PMCollegium Pharmaceutical Inc (NASDAQ:COLL) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:53 AMShare Rating Focus on Collegium Pharmaceutical Inc (NASDAQ:COLL) - HNN
06/02/16 03:05 PMCollegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids - [GlobeNewswire] - CANTON, Mass., June 02, 2016-- Collegium Pharmaceutical, Inc. today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent ...
06/02/16 12:00 PMCollegium Pharmaceutical, Inc. :COLL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/02/16 11:11 AMCollegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 4.9% - HNN - Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 4.9%HNNCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The company has a market cap of $388.40 million. The Firm focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the ...
06/02/16 11:11 AMTarget Price and Stock Performance Rundown for Collegium Pharmaceutical Inc (NASDAQ:COLL) - HNN - Target Price and Stock Performance Rundown for Collegium Pharmaceutical Inc (NASDAQ:COLL)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Collegium Pharmaceutical Inc ...and more »
06/02/16 09:45 AMCollegium to Present at Jefferies and William Blair Conferences - [at noodls] - CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare ...
06/01/16 09:30 PMBroker Watchlist: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Share Trading News - Broker Watchlist: Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Share Trading News05/25/2016 – Collegium Pharmaceutical, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 26 price target on the stock. 03/15/2016 – Janney Montgomery Scott began new coverage on Collegium Pharmaceutical, ...Collegium Pharmaceutical Inc (COLL) Rating Lowered to Sell at Zacks Investment ResearchLet Me Know About ThisCurrent Price Targets For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Risers & Fallersall 4 news articles »
05/31/16 09:04 PMThe Growth Forecast For Collegium Pharmaceutical Inc (NASDAQ:COLL) - RealistInvestor.com - The Growth Forecast For Collegium Pharmaceutical Inc (NASDAQ:COLL)RealistInvestor.comWall Street renowned brokerages following Collegium Pharmaceutical Inc (NASDAQ:COLL) have now given a mean price target of $29.25 on its stock. After accomplishing a methodical study, the analysts have specified a target price range. The intense high ...
05/31/16 12:14 AMAfter Last Week What Do Analysts Think Of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Share Trading News - After Last Week What Do Analysts Think Of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Share Trading News05/25/2016 – Collegium Pharmaceutical, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 26 price target on the stock. 03/15/2016 – Janney Montgomery Scott began new coverage on Collegium Pharmaceutical, ...
05/23/16 03:36 PMCollegium Hosting Investor Day Event on May 25, 2016 - [at noodls] - CANTON, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25 at the St. Regis Hotel in New York City (2 East 55 Street). The ...
05/12/16 04:23 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial -
05/11/16 07:42 AMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 10-Q, Quarterly Report -
05/11/16 05:42 AMCollegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting - [at noodls] - CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of ...
05/10/16 05:02 PMCollegium Pharmaceutical posts 1Q loss -
04/26/16 06:20 PMUPDATE 1-Collegium Pharma's opioid painkiller gets U.S. approval - April 26 (Reuters) - Collegium Pharmaceutical Inc said on Tuesday the U.S. Food and Drug Administration approved its abuse-deterrent painkiller, more than five months after the drug received...
04/17/16 02:03 PMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Updated Analyst Coverage - Risers & Fallers - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL). According to the latest broker reports outstanding on Friday 15th of April, 0 analysts have a rating of “strong buy”, ...
04/15/16 04:02 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements -
04/08/16 07:27 AMCollegium to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - CANTON, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company's CEO, will present at the 15th Annual Needham Healthcare ...
04/04/16 10:24 AMEdited Transcript of COLL earnings conference call or presentation 15-Mar-16 11:30am GMT -
04/03/16 01:55 PMCould Collegium Pharmaceutical Inc Change Direction After Today's Huge Increase? - Business Standard Tribune - Could Collegium Pharmaceutical Inc Change Direction After Today's Huge Increase?Business Standard TribuneThe stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) is a huge mover today! The stock increased 6.70% or $1.14 during the last trading session, hitting $18.15. About 183,587 shares traded hands or 6.64% up from the average. Collegium ...
04/03/16 01:55 PMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker Price Targets For The Coming Week - Share Trading News - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL). The latest reports which are currently in issue on Sunday 3rd of April state 3 analysts have a rating of “strong buy”, 2 ...and more »
04/03/16 01:55 PMPiper Jaffray Lowers stake in Collegium Pharmaceutical Inc (COLL) - Los Angeles Mirror - Piper Jaffray Lowers stake in Collegium Pharmaceutical Inc (COLL)Los Angeles MirrorCollegium Pharmaceutical Inc (COLL) : Piper Jaffray reduced its stake in Collegium Pharmaceutical Inc by 25.13% during the Q4 period. The investment management company now holds a total of 599 shares of Collegium Pharmaceutical Inc which is valued ...Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Shorted Shares Increased By 8.22%Stock CallerBrokers at William Blair rated Collegium Pharmaceutical Inc (NASDAQ:COLL) to Announces,Initiates Coverage on ...The Duncan Independent (press release) (blog)all 3 news articles »
03/26/16 02:02 PMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker Views - Risers & Fallers - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL). According to the latest broker reports outstanding on Thursday 24th of March, 3 analysts have a rating of “strong buy”, ...
03/26/16 02:02 PMRating Update for Collegium Pharmaceutical Inc (NASDAQ:COLL) - Business Standard Tribune - Rating Update for Collegium Pharmaceutical Inc (NASDAQ:COLL)Business Standard TribuneSell-side analysts currently have an average broker rating of 1.2 on shares of Collegium Pharmaceutical Inc (NASDAQ:COLL). This rating averages all the recommendations from analysts that are taken into consideration by Zacks Research. Using a ...and more »
03/26/16 02:02 PMBRIEF-Frazier Healthcare VI, LP reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12, 2015 - SEC filing - Reuters - BRIEF-Frazier Healthcare VI, LP reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12, 2015 - SEC filingReutersBRIEF-Frazier Healthcare VI, L.P. reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12, 2015 - SEC filing. March 24. March 24 (Reuters) -. * Frazier healthcare VI, L.P. Reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12 ...
03/24/16 01:48 PMBRIEF-Frazier Healthcare VI, L.P. reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12, 2015 - SEC filing - * Frazier healthcare VI, L.P. Reports 9.07 pct stake in Collegium Pharmaceutical Inc as of May 12, 2015 - SEC filing Source text (http://1.usa.gov/1ZxgKfr) Further company coverage:
03/24/16 12:04 PMCOLLEGIUM PHARMACEUTICAL, INC Financials -
03/23/16 01:36 PMCollegium Pharmaceutical Inc Increases Again; Strong Momentum for Buyers - Business Standard Tribune - Collegium Pharmaceutical Inc Increases Again; Strong Momentum for BuyersBusiness Standard TribuneThe stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) is a huge mover today! The stock is up 7.06% or $1.15 after the news, hitting $17.44 per share. About 94,186 shares traded hands. Collegium Pharmaceutical Inc (NASDAQ:COLL) has declined ...Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 47.77%SmallCapWired.comChanges To Broker Targets On Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Share Trading NewsCollegium Pharmaceutical Inc (NASDAQ:COLL) Street Rating in FocusUptick Analystall 4 news articles »
03/18/16 04:11 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 10-K, Annual Report -
03/16/16 04:01 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
03/15/16 09:20 AMHuge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids -
03/15/16 06:30 AMCollegium Pharmaceutical Inc Earnings Call scheduled for 7:30 am ET today -
03/15/16 05:23 AMCollegium Pharmaceutical posts 4Q loss -
03/15/16 05:00 AMCollegium Reports 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - CANTON, Mass., March 15, 2016-- Collegium Pharmaceutical, Inc. today reported its 2015 financial results and provided a corporate update.. “Over the last few months, we made significant progress to advance ...
03/14/16 01:53 PMEarnings Per Share for Collegium Pharmaceutical Inc (COLL) Expected to Decline - OctaFinance.com - Earnings Per Share for Collegium Pharmaceutical Inc (COLL) Expected to DeclineOctaFinance.comAnalysts await Collegium Pharmaceutical Inc (NASDAQ:COLL) to reports earnings on March, 15 before the open. After $-0.46 actual earnings per share reported by Collegium Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 4.35 ...
03/12/16 01:51 PMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker Updates - Risers & Fallers - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL). According to the latest broker reports outstanding on Friday 11th of March, 2 analysts have a rating of “strong buy”, ...
03/12/16 01:51 PMCollegium Pharmaceutical, Inc Pipeline Review, Industry Analysis, Market Size and Forecast 2016 – 2020 - Medgadget.com (blog) - Collegium Pharmaceutical, Inc Pipeline Review, Industry Analysis, Market Size and Forecast 2016 – 2020Medgadget.com (blog)“Collegium Pharmaceutical, Inc Pipeline Review, H2 2015”, provides an overview of the Collegium Pharmaceutical, Inc 's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Collegium Pharmaceutical, Inc ...and more »
03/10/16 04:30 PMCollegium to Host Conference Call to Discuss 2015 Financial Results and Provide Corporate Update - [GlobeNewswire] - CANTON, Mass., March 10, 2016-- Collegium Pharmaceutical, Inc. announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET. The Company ...
03/08/16 01:31 PMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Updates - Risers & Fallers - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL). According to the latest broker reports outstanding on Tuesday 8th of March, 2 analysts have a rating of “strong buy”, ...
About Collegium Pharmaceutical

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: COLL
  • CUSIP:
Key Metrics:
  • Previous Close: $12.93
  • 50 Day Moving Average: $15.69
  • 200 Day Moving Average: $18.50
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $304.20M
  • Current Quarter EPS Consensus Estimate: $-3.12 EPS
Additional Links:
Collegium Pharmaceutical (NASDAQ:COLL) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha